| Basics |
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders.
|
| IPO Date: |
October 5, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$6.98B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.81 | 2.90%
|
| Avg Daily Range (30 D): |
$2.02 | 1.95%
|
| Avg Daily Range (90 D): |
$1.73 | 1.73%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.41M |
| Avg Daily Volume (30 D): |
.58M |
| Avg Daily Volume (90 D): |
.49M |
| Trade Size |
| Avg Trade Size (Sh.): |
68 |
| Avg Trade Size (Sh.) (30 D): |
43 |
| Avg Trade Size (Sh.) (90 D): |
38 |
| Institutional Trades |
| Total Inst.Trades: |
2,773 |
| Avg Inst. Trade: |
$2.6M |
| Avg Inst. Trade (30 D): |
$5.66M |
| Avg Inst. Trade (90 D): |
$6.31M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.65M |
| Avg Closing Trade (30 D): |
$9.26M |
| Avg Closing Trade (90 D): |
$10.53M |
| Avg Closing Volume: |
100.98K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-3.1
|
$-.82
|
$-.75
|
|
Diluted EPS
|
$-3.1
|
$-.82
|
$-.75
|
|
Revenue
|
$ 174.33M
|
$ 51.3M
|
$ 48.5M
|
|
Gross Profit
|
$ 155.86M
|
$ 45.8M
|
$ 42.96M
|
|
Net Income / Loss
|
$ -192.33M
|
$ -52.9M
|
$ -46.63M
|
|
Operating Income / Loss
|
$ -186.21M
|
$ -52.65M
|
$ -45.3M
|
|
Cost of Revenue
|
$ 18.48M
|
$ 5.5M
|
$ 5.54M
|
|
Net Cash Flow
|
$ 3.77M
|
$ -83.67M
|
$ 29.83M
|
|
PE Ratio
|
|
|
|
|
|
|
